Innovent Biologics (HK:1801) has released an update.
Innovent Biologics has announced that China’s National Medical Products Administration has approved Dupert® (fulzerasib), a novel treatment for adult patients with advanced non-small cell lung cancer with specific KRAS G12C mutations. The approval is based on promising Phase 2 clinical trial results, showing a high objective response and disease control rate among participants. This breakthrough positions Dupert® as the first approved KRAS G12C inhibitor in China, offering new hope for patients with this genetic mutation in lung cancer.
For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.
